Cargando…

Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease

BACKGROUND: Kawasaki disease (KD) is the most common pediatric systemic vasculitides of unknown etiology. Recent clinical studies led to reappraisal of the usefulness of initial combination therapy of intravenous immunoglobulin (IVIG) plus a corticosteroid for patients with severe KD. However, the m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Takashi, Murakami, Shokei, Matsumoto, Kenji, Matsuda, Akio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539408/ https://www.ncbi.nlm.nih.gov/pubmed/33023630 http://dx.doi.org/10.1186/s12969-020-00461-6

Ejemplares similares

Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease
por: Kitoh, Toshiyuki, et al.
Publicado: (2021)

Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
por: Wang, Zhouping, et al.
Publicado: (2020)

Factors Predicting Resistance to Intravenous Immunoglobulin and Coronary Complications in Kawasaki Disease: IVIG Resistance in Kawasaki Disease
por: Han, Ji Whan
Publicado: (2017)

Correlation between the Level of Inflammatory Cytokines and Prognosis in Children with IVIG-sensitive Kawasaki Disease and IVIG-resistant Kawasaki Disease
por: Zhang, Hao, et al.
Publicado: (2022)

Tenascin-C predicts IVIG non-responsiveness and coronary artery lesions in kawasaki disease in a Chinese cohort
por: Li, Yujie, et al.
Publicado: (2022)

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)

A Case of Kawasaki Disease with Coronary Aneurysm Responding to the 4th IVIG Treatment
por: Kim, Ju Young, et al.
Publicado: (2014)

The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease
por: Samadli, Sama, et al.
Publicado: (2019)

Therapeutic Window of Intravenous Immunoglobulin (IVIG) and its correlation with IVIG-resistant in Kawasaki Disease: a retrospective study
por: Cai, Jiang Hui, et al.
Publicado: (2022)

Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol
por: Eleftheriou, Despina, et al.
Publicado: (2023)

A Replication Study for Association of ITPKC and CASP3 Two-Locus Analysis in IVIG Unresponsiveness and Coronary Artery Lesion in Kawasaki Disease
por: Kuo, Ho-Chang, et al.
Publicado: (2013)

Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection
por: Dionne, Audrey, et al.
Publicado: (2018)

Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease
por: Zhang, Rui Long, et al.
Publicado: (2020)

Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review
por: Crayne, Courtney B., et al.
Publicado: (2019)

Chronic, eventually fatal, Kawasaki-like disease in an adult with spondylarthropathy responding to IVIG therapy
por: Soltner, Elise, et al.
Publicado: (2009)

An antivenin resistant, IVIg-corticosteroids responsive viper induced thrombocytopenia
por: Turetta, Matteo, et al.
Publicado: (2022)

PTX3 promotes IVIG resistance-induced endothelial injury in Kawasaki disease by regulating the NF-κB pathway
por: Sun, Ye, et al.
Publicado: (2023)

DC-SIGN gene promoter variants and IVIG treatment response in Kawasaki disease
por: Portman, Michael A, et al.
Publicado: (2013)

Corticosteroid Therapy Might be Associated with the Development of Coronary Aneurysm in Children with Kawasaki Disease
por: Zhao, Chun-Na, et al.
Publicado: (2016)

An Update on Reports of Atypical Presentations of Kawasaki Disease and the Recognition of IVIG Non-Responder Children
por: Conte, Cristiano, et al.
Publicado: (2023)

Multicenter, Single-Arm, Phase IV Study of Combined Aspirin and High-Dose “IVIG-SN” Therapy for Pediatric Patients with Kawasaki Disease
por: Yoon, Kyung Lim, et al.
Publicado: (2017)

Association of CCR2-CCR5 Haplotypes and CCL3L1 Copy Number with Kawasaki Disease, Coronary Artery Lesions, and IVIG Responses in Japanese Children
por: Mamtani, Manju, et al.
Publicado: (2010)

Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients
por: Wang, Zhouping, et al.
Publicado: (2020)

Distinctive serum lipidomic profile of IVIG-resistant Kawasaki disease children before and after treatment
por: Chen, Zhen, et al.
Publicado: (2023)

Coronary artery aneurysm in Kawasaki disease
por: Donuru, Achala, et al.
Publicado: (2020)

Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High‐Risk Patients With Kawasaki Disease
por: Ae, Ryusuke, et al.
Publicado: (2020)

A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease
por: Takeshita, Seiichiro, et al.
Publicado: (2017)

IVIG treatment for repeated hypothermic attacks associated with LGI1 antibody encephalitis
por: Hayashi, Yuichi, et al.
Publicado: (2017)

Catastrophic Kawasaki disease unresponsive to IVIG in a 3-month-old infant: a diagnostic and therapeutic challenge
por: de Magalhães, Cristina Medeiros Ribeiro, et al.
Publicado: (2012)

Decreased Steroid Hormone Receptor NR4A2 Expression in Kawasaki Disease Before IVIG Treatment
por: Huang, Ying-Hsien, et al.
Publicado: (2019)

Clinical implications of procalcitonin in Kawasaki disease: a useful candidate for differentiating from sepsis and evaluating IVIG responsiveness
por: Niu, Man Man, et al.
Publicado: (2021)

Segmented Coronary Artery Aneurysms and Kawasaki Disease
por: Moghadam, Mohammad Yoosef Aarabi, et al.
Publicado: (2011)

Insights Into Coronary Artery Lesions in Kawasaki Disease
por: Zhang, Danfeng, et al.
Publicado: (2020)

Intimal thickening and disruption of the media occur in the arterial walls of coronary arteries not associated with coronary arterial aneurysms in patients with Kawasaki disease
por: Tsuchihashi, Tomoya, et al.
Publicado: (2021)

A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease
por: Zhu, Bo-hui, et al.
Publicado: (2011)

Coronary artery aneurysm complicated by pneumothorax with a history of Kawasaki disease
por: Ishida, Shinichi, et al.
Publicado: (2021)

Combination of fecal calprotectin and initial coronary dimensions to predict coronary artery lesions persistence in Kawasaki disease
por: Fabi, Marianna, et al.
Publicado: (2022)

Persistence of endothelial cell damage late after Kawasaki disease in patients without coronary artery complications
por: Mostafavi, Nasser, et al.
Publicado: (2015)

Phosphorylated proteomics analysis of human coronary artery endothelial cells stimulated by Kawasaki disease patients serum
por: Li, Shui-Ming, et al.
Publicado: (2019)

Major methylation alterations on the CpG markers of inflammatory immune associated genes after IVIG treatment in Kawasaki disease
por: Li, Sung-Chou, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mvkkpe99m7bsf5n7v0uiomdo04